eDC Technology

Renewable human APC systems for antigen-specific research and custom engineering.

Renewable, antigen-defined APC systems

The eDC platform provides a cellular foundation for studying antigen-specific immune function and engineering APC configurations around defined research questions.

eDC (engineered dendritic cells) are renewable human antigen-presenting cell lines established from primary blood cells. They keep a mature, activated dendritic cell phenotype in culture, expand to supply repeated experiments, and accept a defined antigen and agreed gene modifications. The eDC system is the basis of the APC drug discovery platform.

The platform brings together antigen-expressing eDC lines, paired target cell assay systems and supporting culture cytokines. Custom development begins with customer-provided PBMCs and may include agreed genetic modifications.

01Antigen-defined eDC

Specific antigen configuration

02Immune response

T cells suited to the study

03Functional test

Matched target and controls

Conceptual study framework; not experimental data.

Mature, activated dendritic cell phenotype

Flow cytometry shows a lineage-negative, myeloid dendritic cell profile with antigen presentation, costimulatory and lymph node homing markers. CrossRelay reports that eDCs prime naïve T cells to antigen-specific cytotoxic effector cells; the underlying work is published. [PNAS 2018]

Flow cytometry histograms of eDCs for 15 markers: CD3, CD14, CD19, CD56, CD11c, CD205, HLA-ABC, HLA-DR, CCR7, CD40, CD83, CD80, CD86, CD70 and 4-1BBL.

eDC immunophenotype. Single-parameter histograms for 15 markers, with the gate values printed on the panel. Red and cyan traces are shown as in the source figure. Control definition, line identity, passage and gating are not stated on this page, so the panel is descriptive and is not a release specification.

Antigen presentation

HLA-ABC (99.9), HLA-DR (99.9)

Costimulation and activation

CD80 (99.7), CD86 (99.6), CD83 (98.4), CD40 (90.4), CD70 (100.0); 4-1BBL (27.2, modest shift)

Migration

CCR7 (100)

Myeloid dendritic cell identity

CD11c (94.7), CD205 (99.2)

Lineage markers, not shifted

CD3 (0.44), CD14 (0.98), CD19 (0.54), CD56 (0.73)

Values in brackets are the gate percentages printed on the panel. Groups summarize histogram shifts relative to the overlaid trace. The panel does not assign an eDC to a classical DC subset and does not establish priming function, which requires functional assays.

eDC in adherent growth with dendritic processes
Adherent growth. Some eDCs show typical dendrites.
eDC in suspension growth with cell surface projections
Suspension growth. Most eDCs grow in suspension with a clumped pattern and cell surface projections.

Original phase-contrast micrographs shown at native size. Magnification, scale bars and line identity are not specified. Morphology does not establish antigen-specific function.

eDC technology compared with the conventional MoDC method

MoDCs are the most widely characterized DC format in research. The approved autologous product sipuleucel-T is made from blood mononuclear cells that include antigen-presenting cells, so it is not a pure MoDC preparation. [24] The table lists characteristics reported by CrossRelay for eDC; confirm each parameter on the specific line.

FeatureConventional MoDC methodeDC technology
Starting materialDonor monocytes, often from leukapheresis in a hospital settingPrimary PBMCs; a small blood draw is the described starting sample
Growth in cultureDifferentiated from monocytes with GM-CSF and IL-4; not propagatedGrows in culture, supplying cells for repeated experiments
Maturation and activationAdditional cytokines or TLR ligands are added after differentiationMature, activated phenotype maintained in culture
StandardizationDonor-dependent yield and qualityOne defined line across experiments
Genetic modification and antigen loadingLower efficiency, as reportedLentiviral transduction, mRNA-LNP, and antigen uptake with cross-presentation
FormatAutologousAutologous, or HLA-matched allogeneic
Lymphoid homingLower, as reportedCCR7 expressed; homing function requires testing in the intended model
StorageShort-termLong-term cryostorage; viability above 85% is reported for eDC
Read the balanced DC-method comparison

Connect the components of the experiment

ComponentResearch roleExplore
Antigen-expressing eDCProvides an APC configuration around the study antigeneDC lines ›
Paired target cellEnables functional assessment with antigen/HLA comparisonsPaired systems ›
Supporting cytokinesSupports connected immune cell culture workflowsCulture support ›
Custom modificationsEnables project-specific APC gene function questionsCustom services ›

Characterize the selected configuration

For repeated experiments, assess renewal alongside antigen expression and functional activity at the relevant passages. For gene function studies, confirm the requested modification and include matched controls.

Explore representative functional data
Choose the model for the experiment

MoDCs and progenitor-derived DCs are useful research systems. Compare antigen/HLA matching, culture context and the actual functional endpoint before selecting an eDC configuration.

Read the balanced DC-method comparison

Research applications

Build the assay around the endpoint: antigen-specific response, target cell function or the effect of a selected APC gene modification.

Explore research applications

See how the platform supports target discovery and validation

Scientific support for your experiment

Discuss your antigen, HLA context, study controls and custom engineering requirements.

Explore scientific support